Theriva Biologics reveals positive VCN-01 study results
The candidate is a stroma-degrading oncolytic adenovirus for the treatment of pancreatic cancer
Read More
Tag: vcn-01
- ErVimmune raises 17m euros in funding to develop cancer vaccine
- Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
